Alto Neuroscience Quote - ANRO

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

3.94

Bid

Ask

Volume

432,206

3.66 Day's Range 3.93

3.56 52 Week Range 24.00

Market Cap

106.262M

Previous Close

3.72

Open

3.76

Last Trade

165432

3.89

Last Trade Time

Financial Volume

US$ 1,645,117

VWAP

3.8063

Average Volume (3m)

783,303

Shares Outstanding

26,970,168

Dividend Yield

PE Ratio

-2.88

Earnings Per Share (EPS)

-1.35

Revenue

Net Profit

-36.31M

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients' b... Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients' brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.altoneuroscience.com

Headquarters

Wilmington, Delaware, USA

Founded

Alto Neuroscience Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker ANRO. The last closing price for Alto Neuroscience was US$3.72. Over the last year, Alto Neuroscience shares have traded in a share price range of US$ 3.56 to US$ 24.00.

Alto Neuroscience currently has 26,970,168 shares outstanding. The market capitalization of Alto Neuroscience is US$100.33 million. Alto Neuroscience has a price to earnings ratio (PE ratio) of -2.88.

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

– Data generated from Alto’s precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion – – New preclinical data from...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– Topline data from two MDD trials expected in the first half of 2025: Phase 2b trial of ALTO-300 as an adjunctive treatment and Phase 2a trial of ALTO-203 in patients with anhedonia – –...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced...

Form 8-K - Current report

Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder

– Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker – – ALTO-100 demonstrated a favorable...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.11	2.87206266319	3.83	4.09	3.56	314794	3.74919854	CS
4	-0.15	-3.66748166259	4.09	4.53	3.56	311164	3.96956274	CS
12	-8.21	-67.5720164609	12.15	15.04	3.56	783303	5.89506692	CS
26	-7.36	-65.1327433628	11.3	17.55	3.56	503568	7.64896037	CS
52	-18.06	-82.0909090909	22	24	3.56	368493	9.33344264	CS
156	-18.06	-82.0909090909	22	24	3.56	368493	9.33344264	CS
260	-18.06	-82.0909090909	22	24	3.56	368493	9.33344264	CS

ANRO - Frequently Asked Questions (FAQ)

What is the current Alto Neuroscience share price?

The current share price of Alto Neuroscience is US$ 3.94

How many Alto Neuroscience shares are in issue?

Alto Neuroscience has 26,970,168 shares in issue

What is the market cap of Alto Neuroscience?

The market capitalisation of Alto Neuroscience is USD 100.33M

What is the 1 year trading range for Alto Neuroscience share price?

Alto Neuroscience has traded in the range of US$ 3.56 to US$ 24.00 during the past year

What is the PE ratio of Alto Neuroscience?

The price to earnings ratio of Alto Neuroscience is -2.88

What is the reporting currency for Alto Neuroscience?

Alto Neuroscience reports financial results in USD

What is the latest annual profit for Alto Neuroscience?

The latest annual profit of Alto Neuroscience is USD -36.31M

What is the registered address of Alto Neuroscience?

The registered address for Alto Neuroscience is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Alto Neuroscience website address?

The website address for Alto Neuroscience is www.altoneuroscience.com

Which industry sector does Alto Neuroscience operate in?

Alto Neuroscience operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
VNCEVince Holding Corp	US$ 4.70 (69.06%)	1.06M
SRFMSurf Air Mobility Inc	US$ 3.33 (23.79%)	376.77k
BBBlackBerry Limited	US$ 3.685 (23.66%)	40.8M
ALURAllurion Technologies Inc	US$ 0.3439 (22.87%)	744.34k
CLWClearWater Paper Corporation	US$ 30.26 (22.46%)	3.5M
IIPRInnovative Industrial Properties Inc	US$ 73.50 (-22.91%)	3.15M
KUKEKuke Music Holding Limited	US$ 0.31 (-20.51%)	61.48k
NVONovo Nordisk	US$ 85.00 (-17.83%)	53.81M
CANGCango Inc	US$ 5.08 (-11.81%)	2.44M
BNEDBarnes and Noble Education Inc	US$ 9.965 (-10.31%)	1.55M
QBTSD Wave Quantum Inc	US$ 6.638 (4.21%)	124.42M
PFEPfizer Inc	US$ 26.36 (2.29%)	116.33M
APOApollo Global Management Inc	US$ 171.03 (0.83%)	94.52M
TAT&T Inc	US$ 22.75 (0.80%)	93.94M
FFord Motor Company	US$ 9.885 (1.49%)	87.66M